Premium
Adoptive T‐cell transfer in cancer immunotherapy
Author(s) -
Tey SiokKeen,
Bollard Catherine M,
Heslop Helen E
Publication year - 2006
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1111/j.1440-1711.2006.01441.x
Subject(s) - adoptive immunotherapy , immunology , immunotherapy , adoptive cell transfer , antigen , cell therapy , t cell , cancer immunotherapy , virology , genetic enhancement , immune system , medicine , biology , cell , gene , genetics
Adoptive T‐cell therapy has definite clinical benefit in relapsed leukaemia after allogeneic transplant and in Epstein–Barr virus‐associated post‐transplant lymphoproliferative disease. However, the majority of tumour targets are weakly immunogenic self‐antigens and success has been limited in part by inadequate persistence and expansion of transferred T cells and by tumour‐evasion strategies. Adoptive immunotherapy presents the opportunity to activate, expand and genetically modify T cells outside the tolerising environment of the host and a number of strategies to optimize the cellular product, including gene modification and modulation of the host environment, in particular by lymphodepletion, have been developed.